A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors

被引：0
|
作者：
Takiuchi, Hiroya
Gotoh, Masahiro
Yoshida, Motoki
Kii, Takayuki
Yamashita, Keishi
Sunakawa, Yu
Kaneta, Toshikado
Robson, Matthew
Kakizume, Tomoyuki
Sasaki, Yasutsuna
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Osaka Med Coll Hosp, Osaka, Japan
[3] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[4] Novartis Pharma KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3088
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3
    Milowsky, Matthew I.
    Dittrich, Christian
    Martinez, Ignacio Duran
    Jagdev, Satinder
    Millard, Frederick E.
    Sweeney, Christopher
    Bajorin, Dean F.
    Cerbone, Linda
    Dunn, Robert M.
    Sen, Paramita
    Shi, Michael
    Kay, Andrea C. M.
    Squires, Matthew
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [42] The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma
    Shi, M. M.
    Motwani, M.
    Wang, J.
    Steed, M.
    Dohoney, K.
    Saro, J.
    Wasserman, R.
    Barrett, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation
    Scheid, Christof
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Callander, Natalie
    Sonneveld, Pieter
    Kalimi, Ghulam
    Cai, Can
    Shi, Michael
    Scott, Jeffrey W.
    Stewart, A. Keith
    BLOOD, 2012, 120 (21)
  • [44] A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
    Wataru Okamoto
    Takayuki Yoshino
    Toshiaki Takahashi
    Isamu Okamoto
    Shinya Ueda
    Asuka Tsuya
    Narikazu Boku
    Kazuto Nishio
    Masahiro Fukuoka
    Nobuyuki Yamamoto
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1063 - 1071
  • [45] A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
    Okamoto, Wataru
    Yoshino, Takayuki
    Takahashi, Toshiaki
    Okamoto, Isamu
    Ueda, Shinya
    Tsuya, Asuka
    Boku, Narikazu
    Nishio, Kazuto
    Fukuoka, Masahiro
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1063 - 1071
  • [46] Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding
    Wang, X.
    Saro, J.
    Wei, Z.
    Shi, M. M.
    Xia, J.
    Jones, G.
    Bruckmann, K.
    Wisniewski, L.
    Schran, H. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A phase II study of the VEGFR- and FGFR-inhibitior Dovitinib (TKI258) in patients with refractory advanced or metastatic renal cell cancer previously treated with VEGFR- or mTOR-targeted therapy
    Gruenwald, V
    Retz, M.
    Fenner, M.
    Wang, Y.
    Chang, J.
    Kay, A.
    Zuern, C.
    Gschwend, J.
    ONKOLOGIE, 2011, 34 : 11 - 11
  • [48] Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2/HR+ breast cancer: a phase II study
    Andre, F.
    Greil, R.
    Denduluri, N.
    Barrios, C.
    Campone, M.
    Cortes, J.
    Neven, P.
    Reddick, C.
    Squires, M.
    Zhang, Y.
    Yovine, A.
    Blackwell, K.
    CANCER RESEARCH, 2012, 72
  • [49] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [50] A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors
    Watanabe, K.
    Otsu, S.
    Hirashima, Y.
    Morinaga, R.
    Nishikawa, K.
    Hisamatsu, Y.
    Shimokata, T.
    Inada-Inoue, M.
    Shibata, T.
    Takeuchi, H.
    Watanabe, T.
    Tokushige, K.
    Maacke, H.
    Shiaro, K.
    Ando, Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1157 - 1164
12345